COVID-19 Pathophysiology and Clinical Effects on Multiple Organ Systems - A Narrative Review
DOI:
https://doi.org/10.21467/ias.10.1.151-167Abstract
Patients with comorbidities including Hypertension (HTN), Diabetes Mellitus (DM), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obesity, Cardiovascular Disease (CVD), Chronic Kidney Disease (CKD), and those who are immunocompromised are prone to more severe complications of COVID-19 and a higher rate of hospitalizations. In the United States, around 94% of COVID-19 deaths had an average of 2.6 additional conditions or causes per death. In a summary report published by the Chinese Centre for Disease Control and Prevention of 72,314 cases, case-fatality rate was elevated among those with preexisting comorbid conditions—10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for HTN, and 5.6% for cancer. The COVID-19 pandemic continues to threaten people and healthcare systems globally and therefore the global economy. Currently, there is no cure or vaccine for COVID-19 and there is an urgent need to develop target therapies as we continue to learn more about this novel virus. Without therapeutic interventions, much of how we contain the viral spread is prevention through mitigation strategies (social distancing, face masks, supportive care). Early suspicion of COVID-19 symptoms with radiological and laboratory assessments may play a major role in preventing severity of the COVID-19. With this literature review we aim to provide review of pathophysiology of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and its clinical effects on multiple organ systems.
Keywords:
COVID-19, Pathophysiology, Clinical EffectsDownloads
References
China CDC Weekly (2020). Vital surveillance: The epidemiological characteristics of an outbreask of 2019. Novel Coronoavirus Disease (COVID-19). 2(8): 113-122. doi: 10.46234/ccdcw2020.032 Accessed on April 25, 2021 https://scholar.harvard.edu/files/kleelerner/files/20200217_ccdc_-_the_epidemiological_characteristics_of_an_outbreak_of_2019_novel_coronavirus_diseases_covid-19_-_china_cdc.pdf
Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020). Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology, 296(2), E15–E25. https://doi.org/10.1148/radiol.2020200490
Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity, 109, 102433. https://doi.org/10.1016/j.jaut.2020.102433
Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. Life Sci. 2020;255:117839. doi:10.1016/j.lfs.2020.117839
Centers for Disease Control and Prevention. (2020). COVID-19 Associated Hospitalization Related to Underlying Medical Conditions. Centers for Disease Control and Prevention. Accessed April 25, 2021 from https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-underlying-medical-conditions.html
Centers for Disease Control and Prevention. (2020, September 23). COVID-19 Provisional Counts - Weekly Updates by Select Demographic and Geographic Characteristics. Centers for Disease Control and Prevention. Accessed on April 25, 2020 from https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?fbclid=IwAR3-wrg3tTKK5-9tOHPGAHWFVO3DfslkJ0KsDEPQpWmPbKtp6EsoVV2Qs1Q.
World Health Organization. (2020). Advice for the public on COVID-19. World Health Organization. Accessed on April 25, 2021 from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
Berardi, A., Perinelli, D. R., Merchant, H. A., Bisharat, L., Basheti, I. A., Bonacucina, G., … Palmieri, G. F. (2020). Hand sanitisers amid CoViD-19: A critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand. International Journal of Pharmaceutics, 584, 119431. https://doi.org/10.1016/j.ijpharm.2020.119431
Eikenberry, S. E., Mancuso, M., Iboi, E., Phan, T., Eikenberry, K., Kuang, Y., … Gumel, A. B. (2020). To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infectious Disease Modelling, 5, 293–308. https://doi.org/10.1016/j.idm.2020.04.001
Gandhi,M., Beyrer,C., Goosby,E. (2020). Masks do more than protect others during COVID-19: reducing the inoculum of SARS-CoV-2 to protect the wearer. Journal of General Internal Medicine. 2020 Oct, 35(10): 3063-3066
Zhi, Z. (2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Retrieved September 14, 2020, from https://pubmed.ncbi.nlm.nih.gov/32064853/
WHO. (2020). Novel Coronavirus (2019-nCoV) Situation Report-1. Retrieved September 14, 2020, from https:// www.who.int/docs/default-source/coronaviruse/situationreports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
WHO. (2020). Coronavirus disease 2019 (COVID-19) Situation Report-26. Retrieved September 14, 2020, from https:// www.who.int/docs/default-source/coronaviruse/situationreports/20200215-sitrep-26-covid-19.pdf?sfvrsn=a4cc6787_2
Holshue, M., DeBolt, C., Lindquist, S., Lofy, K., Wiesman, J., Bruce, H. et al. First case of 2019 novel coronavirus in the united states. New England Journal of Medicine 2020; 382: 929-936. Doi: 10.1056/NEJMoa2001191
Bashir MF, Ma B, Bilal, Komal B, Bashir MA, Tan D, Bashir M. Correlation between climate indicators and COVID-19 pandemic in New York, USA. Sci Total Environ. 2020 Aug 1;728:138835. doi: 10.1016/j.scitotenv.2020.138835. Epub 2020 Apr 20. PMID: 32334162; PMCID: PMC7195034.
Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr Infect Dis J. 2020 May;39(5):355-368. doi: 10.1097/INF.0000000000002660. PMID: 32310621; PMCID: PMC7158880.
WHO (2020). Coronavirus disease (COVID-19) weekly epidemiological update. Retrieved September 15, 2020, from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200914-weekly-epi-update-5.pdf?sfvrsn=cf929d04_2
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020 May;55(5):105955. doi: 10.1016/j.ijantimicag.2020.105955. Epub 2020 Mar 28. PMID: 32234468; PMCID: PMC7138178.
Yang, Y., Lu, Q., Liu, M., Wang, Y., Zhang, A., Jalali, N., et al. (2020) Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. MedRxiv preprint doi: https://doi.org/10.1101/2020.02.10.20021675
Zhang, H., Penninger, J., Li, Y., Zhong N., Slutsky, A. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med (2020) 46: 586-590
Hu, Y., Sun, J., Dai, Z., et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Viro. 2020 Jun; 127:104371. Doi:10.1016j.jcv.2020.10447
Chu, H., Chan, JF., Wang, Y., Yen TT., et al. Comparative replication and Immune Activation Profile of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. Doi:10.1093/cid/ciaa410.PMID:32270184; PMCID:PMC7184390.
Ackermann, M., Verleden, S., Kuehnel, M., Haverich, A. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med 2020; 383:120-128. DOI 10.1056NEJMoa2015432
Guoping, L., Xiang, H., Zhang, L, Ran, Q. et al. Assessing ACE2 expression patterns in lung tissues in the pathogensis of COVID-19. J Autoimmun. 2020 Aug; 112:102463. Doi 10.1016/j.jaut.2020.102463.
Li, X., Ma, X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit Care. 2020; 24: 198. Doi 10.1186/s13054-020-02911-9.
American Lung Association (2020). What is COVID-19. Retrieved on April 25, 2021 from https://www.lung.orlung-health-disease/lung-disease-lookup/covid-19/about-covid-19 Accessed September 30, 2020
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID: 32139904; PMCID: PMC7095524.
Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020 May-Jun;14(3):247-250. doi: 10.1016/j.dsx.2020.03.013. Epub 2020 Mar 25. PMID: 32247212; PMCID: PMC7102662.
Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y, Han Y. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020 Aug;106(15):1132-1141. doi: 10.1136/heartjnl-2020-317056. Epub 2020 Apr 30. PMID: 32354800; PMCID: PMC7211105.
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11. PMID: 32161990; PMCID: PMC7087935.
Ye, Q., Wang, B., Mao, J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020 Jun; 80(6): 607–613.
Sinha, P., Matthay, M., Calfee, C. Is a “Cytokine Storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152-1154. doi:10.1001/jamainternmed.2020.3313
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J., Rajagopal, S., Pai, A., Kutty, S. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020; 11: 1648.
Mangalmurti, M. & Hunter, C. Cytokine Storms: Understanding COVID-19. Immunity. 2020 Jul 14; 53(1): 19–25.
Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J. et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 Jun; 53: 38-42.
Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med 8: 433–434, 2020. doi:10.1016/S2213-2600(20)30127-2.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. AMA Intern Med. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994. PMID: 32167524, PMCID: PMC7070509
Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S .COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology.Journal of the American Society of Nephrology, July 2020, 31(7): 1380-1383
Husain-Syed et al, F., Slutsky, A. S. & Ronco, C. Lung-kidney cross-talk in the critically ill patient. Am. J. Respir. Crit. Care Med. 194, 402–414 (2016)
Ronco C , Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020; 16: 308–310
Hirsch JS , Ng JH , Ross DW et al. . Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 2020; 98: 209–218
Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, and Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med 46, 1339–1348 (2020). doi: 10.1007/s00134-020-06153-9. Epub 2020 Jun 12. PMID: 32533197; PMCID: PMC7290076.
Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020 Jul; 8(7): 738–742. PMID: 32416769; PMCID: PMC7255232.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.
Tadic, M., Cuspidi, C., & Sala, C. (2020). COVID-19 and diabetes: Is there enough evidence?. Journal of clinical hypertension (Greenwich, Conn.), 22(6), 943–948. https://doi.org/10.1111/jch.13912
Lian, J., Jin, X., Hao, S., Cai, H., Zhang, S., Zheng, L., Jia, H., Hu, J., Gao, J., Zhang, Y., Zhang, X., Yu, G., Wang, X., Gu, J., Ye, C., Jin, C., Lu, Y., Yu, X., Yu, X., Ren, Y., … Yang, Y. (2020). Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(15), 740–747. https://doi.org/10.1093/cid/ciaa242
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet. Respiratory medicine, 8(4), e21. https://doi.org/10.1016/S2213-2600(20)30116-8
Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., Du, K., Zhao, L., Fan, H., Luo, S., & Hu, D. (2020). Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/metabolism research and reviews, e3319. Advance online publication. https://doi.org/10.1002/dmrr.3319
Patel, K. P., Patel, P. A., Vunnam, R. R., Hewlett, A. T., Jain, R., Jing, R., & Vunnam, S. R. (2020). Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 128, 104386. https://doi.org/10.1016/j.jcv.2020.104386
Muniyappa & Gubbi (2020, April 26). COVID-19 pandemic, coronaviruses, and diabetes mellitus: American Journal of Physiology, endocrinology and metabolism. Retrieved from: <https://doi.org/10.1152/ajpendo.00124.2020>
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020). Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes & metabolic syndrome, 14(4), 535–545. https://doi.org/10.1016/j.dsx.2020.04.044
Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & metabolic syndrome, 14(4), 303–310. https://doi.org/10.1016/j.dsx.2020.04.004
Bhaskar S, Rastogi A, Chattu VK, et al. Key Strategies for Clinical Management and Improvement of Healthcare Services for Cardiovascular Disease and Diabetes Patients in the Coronavirus (COVID-19) Settings: Recommendations From the REPROGRAM Consortium. Front Cardiovasc Med. 2020;7:112. Published 2020 Jun 16. doi:10.3389/fcvm.2020.00112
Barclay L, Nyarko E. Are Diabetes, CVD Associated with Worse COVID-19 Prognosis? Medscape (2020). Available online at: https://www.medscape.org/viewarticle/926097 (accessed April 5, 2020).
Ahmed, W. N., Arun, C. S., Koshy, T. G., Nair, A., Sankar, P., Rasheed, S. A., & Ann, R. (2020). Management of diabetes during fasting and COVID-19 - Challenges and solutions. Journal of family medicine and primary care, 9(8), 3797–3806.
Gu, J., Han, B., & Wang, J. (2020). COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral 854 Transmission. Gastroenterology, 158(6), 1518–1519. https://doi.org/10.1053/j.gastro.2020.02.054
Cheong, J., Bartell, N., Peeraphatdit, T., Mosli, M., & Al-Judaibi, B. (2020). Gastrointestinal and liver 856 manifestations of COVID-19. Saudi journal of gastroenterology : official journal of the Saudi 857 Gastroenterology Association, 26(5), 226–232. https://doi.org/10.4103/sjg.SJG_147_20
Cha, M. H., Regueiro, M., & Sandhu, D. S. (2020). Gastrointestinal and hepatic manifestations of COVID-19: 859 A comprehensive review. World journal of gastroenterology, 26(19), 2323–2332. 860 https://doi.org/10.3748/wjg.v26.i19.2323
Baryah, A., Midha, V., Mahajan, R., & Sood, A. (2020). Impact of Corona Virus Disease-19 (COVID-19) 862 pandemic on gastrointestinal disorders. Indian journal of gastroenterology : official journal of the Indian 863 Society of Gastroenterology, 39(3), 214–219. https://doi.org/10.1007/s12664-020-01071-6
Kotfis, K., & Skonieczna-Żydecka, K. (2020). COVID-19: gastrointestinal symptoms and potential sources of 865 SARS-CoV-2 transmission. Anaesthesiology intensive therapy, 52(2), 171–172. 866 https://doi.org/10.5114/ait.2020.93867
Téllez L, Martín Mateos RM. COVID-19 and liver disease: An update [Actualización en COVID-19 y enfermedad hepática]. Gastroenterología y Hepatología (English Edition). 2020;43(8):472-480. doi:10.1016/j.gastre.2020.06.005
Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020 Jul;75(7):1742-1752. doi: 10.1111/all.14309. Epub 2020 Apr 17. PMID: 32239761.
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002. Epub 2020 Apr 10. PMID: 32283325; PMCID: PMC7194865.
Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.
Li L, Li S, Xu M, Yu P, Zheng S, Duan Z, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. March 2020. medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514;
Liu, Wei1; Tao, Zhao-Wu2; Wang, Lei1; Yuan, Ming-Li1; Liu, Kui3; Zhou, Ling3; Wei, Shuang3; Deng, Yan3; Liu, Jing4; Liu, Hui-Guo3; Yang, Ming5; Hu, Yi1 Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease, Chinese Medical Journal: May 5, 2020. 133(9): 1032-1038 doi: 10.1097/CM9.0000000000000775
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Disease. April 01, 2020. 20(4): 425-434. DOI:https://doi.org/10.1016/S1473-3099(20)30086-4
Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, Yu J, Cao H, Li L. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020 Jul;288(1):128-138. doi: 10.1111/joim.13063. Epub 2020 Apr 20. PMID: 32220033.
Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020 Sep;40(9):2095-2103. doi: 10.1111/liv.14455. Epub 2020 Apr 28. PMID: 32239796.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine. 2020;8(4):420-2.
Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS‐associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004;39(2):302-10
Moiseev S, Avdeev S, Brovko M, et al Rheumatic diseases in intensive care unit patients with COVID-19 (2020). Annals of the Rheumatic Diseases. Published as doi: 10.1136/annrheumdis-2020-217676
Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, Andreoli L, Caporali R, Gerli R, Sebastiani GD, Valesini G, Sinigaglia L; Italian Registry of the Italian Society for Rheumatology (CONTROL-19). COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28. PMID: 32723435.
Friedman, N. et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses 10, 515 (2018).
Christian, M. D., Poutanen, S. M., Loutfy, M. R., Muller, M. P. & Low, D. E. Severe acute respiratory syndrome. Clin. Infect. Dis. 38, 1420–1427 (2004).
Li, S. et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am. J. Chin. Med. 34, 937–947 (2006).
Schett, G., Manger, B., Simon, D. et al. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol 16, 465-470 (2020). https://doi.org/10.1038/s41584-020-0451-z
Mikuls R, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. (2020) American College of Rheumatology Guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. Arthritis Rheumatology. September 2020, 72(9): e1-e12. https://doi.org/10.1002/art.41437
Favalli E.G., Biggioggero M., Meroni P.L. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev. 2014;13:1102–1108. doi: 10.1016/j.autrev.2014.08.026
Favalli E.G., Raimondo M.G., Becciolini A., Crotti C., Biggioggero M., Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev. 2017; 16: 1185–1195.
Doi: 10.1016/j.autrev.2017.10.002.
Mark A Ellulet al (2020) Neurological associations of Covid-19. Lancet Neurol 2020; 19: 767–83 https://doi.org/10.1016/ S1474-4422(20)30221-0
Olds JL, Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? FEBS J. 2020 Sep;287(17):3651-3655. Doi: 10.1111/febs.15303. Epub 2020 Mar 28. PMID: 32189428; PMCID: PMC7228237.
McFadden G. Cytokine determinants of viral tropism. Nat. Rev. Immunol. 2009;9(9):645–655.
Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: Underestimated damage to nervous system. Travel Med Infect Dis. 2020; 36: 101642. Doi:10.1016/j.tmaid.2020.101642
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology, 2021; 77(6): 683-690
Berger J. R. (2020). COVID-19 and the nervous system. Journal of neurovirology, 26(2), 143–148. https://doi.org/10.1007/s13365-020-00840-5
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. March 28, 2020. 395(10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Pereira A. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front Neurol. 2020;11:308. Published 2020 Apr 17. Doi:10.3389/fneur.2020.00308
Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 12(1):8
Seiden AM. Postviral olfactory loss. Otolaryngol Clin N Am. 2004;37(6):1159–1166.
doi: 10.1016/j.otc.2004.06.007.
Hopkins C, Kumar N (2020) Loss of sense of smell as a marker of COVID-19 infection. ENTUK [cited 2020 March 30]; Accessed April 25, 2021 from https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf
Downloads
Published
Issue
Section
How to Cite
License
Copyright (c) 2020 Kinal Paresh Bhatt, Jonathan Quinonez, Abhinav Patel, Mehrie Patel, Abdifitah Mohamed, Muhammad Ali Aziz, Deepa Venkataramani, Fatema Zohora, Namrata Hange, Dana Awad, Isha Mehta, Paz Ines M Domingo, Nadia Jamil, Shravika Reddy Kandi, Sindhu Thevuthasan, Uzzam Ahmed Khawaja, Dhanya Baskaran, LaShanthan Banks, George Michel, Marcos Sanchez-Gonzalez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Author(s) retains full copyright of their article and grants non-exclusive publishing right to International Annals of Science and its publisher "AIJR (India)". Author(s) can archive pre-print, post-print, and published version/PDF to any open access, institutional repository, social media, or personal website provided that Published source must be acknowledged with citation and link to publisher version.
Click here for more information on Copyright policy
Click here for more information on Licensing policy
